AstraZeneca/Pfizer Deal Faces Few Hurdles Under EU Antitrust Law
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite loud opposition in the U.K. to a potential AstraZeneca/Pfizer merger due to its possible implications on employment, EU competition rules are unlikely to block it.